Kjeld Kristensen

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

White coat hypertension is a cardiovascular risk factor: a 10-year follow-up study

P. H. Gustavsen, Asbjørn Høegholm, Lia E. Bang et al. · Journal of Human Hypertension · 2003 · 191 citations

Medicine, Cardiology, Epidemiology +11

Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension, and normotension.

Asbjørn Høegholm, Lia E. Bang, Kjeld Kristensen et al. · Hypertension · 1994 · 147 citations · Full text

Medicine, Internal Medicine, Nephrology +15

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo et al. · Journal of the American College of Cardiology · 2021 · 141 citations · Full text

Medicine, Cardiology, Pharmacology +17

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17